A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis C
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This Phase II study is being conducted in treatment-naive patients (no previous antiviral
therapy for Hepatitis C infection) with genotype-1 chronic hepatitis C to evaluate the safety
and effectiveness of valopicitabine alone and together with Pegylated Interferon (a drug
approved by the Food and Drug Administration for the treatment of Hepatitis C infection).